These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 15889137

  • 1. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.
    Wang L, Cao O, Swalm B, Dobrzynski E, Mingozzi F, Herzog RW.
    Gene Ther; 2005 Oct; 12(19):1453-64. PubMed ID: 15889137
    [Abstract] [Full Text] [Related]

  • 2. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.
    Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, McCleland ML, Hagstrom JN, Pasi KJ, Ertl HC, Herzog RW, High KA.
    Mol Ther; 2000 Mar; 1(3):225-35. PubMed ID: 10933938
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
    Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA.
    Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178
    [Abstract] [Full Text] [Related]

  • 6. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
    High KA.
    Trans Am Clin Climatol Assoc; 2003 Mar; 114():337-51; discussion 351-2. PubMed ID: 12813929
    [Abstract] [Full Text] [Related]

  • 7. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects.
    Hasbrouck NC, High KA.
    Gene Ther; 2008 Jun; 15(11):870-5. PubMed ID: 18432276
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
    Herzog RW, Mount JD, Arruda VR, High KA, Lothrop CD.
    Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
    [Abstract] [Full Text] [Related]

  • 11. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.
    Yuasa K, Yoshimura M, Urasawa N, Ohshima S, Howell JM, Nakamura A, Hijikata T, Miyagoe-Suzuki Y, Takeda S.
    Gene Ther; 2007 Sep; 14(17):1249-60. PubMed ID: 17581597
    [Abstract] [Full Text] [Related]

  • 12. Persistent expression of canine factor IX in hemophilia B canines.
    Chao H, Samulski R, Bellinger D, Monahan P, Nichols T, Walsh C.
    Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
    [Abstract] [Full Text] [Related]

  • 13. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
    Yuasa K, Sakamoto M, Miyagoe-Suzuki Y, Tanouchi A, Yamamoto H, Li J, Chamberlain JS, Xiao X, Takeda S.
    Gene Ther; 2002 Dec; 9(23):1576-88. PubMed ID: 12424610
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice.
    Rivière C, Danos O, Douar AM.
    Gene Ther; 2006 Sep; 13(17):1300-8. PubMed ID: 16688207
    [Abstract] [Full Text] [Related]

  • 19. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice.
    Fields PA, Armstrong E, Hagstrom JN, Arruda VR, Murphy ML, Farrell JP, High KA, Herzog RW.
    Gene Ther; 2001 Mar; 8(5):354-61. PubMed ID: 11313811
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector.
    Liu YL, Mingozzi F, Rodriguéz-Colôn SM, Joseph S, Dobrzynski E, Suzuki T, High KA, Herzog RW.
    Hum Gene Ther; 2004 Aug; 15(8):783-92. PubMed ID: 15319035
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.